Navigation Links
BioSpecifics Technologies Corp. To Present at BioCentury 'NewsMakers in the Biotech Industry' Conference
Date:9/11/2009

LYNBROOK, N.Y., Sept. 11 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming BioCentury "NewsMakers in the Biotech Industry" Conference on Wednesday, September 16, 2009, at 9:00 am ET at the Millennium Broadway Hotel & Conference Center in New York, NY.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BSTC&item_id=2413263.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX product in Europe.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 11th Annual Healthcare Conference
2. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
3. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
4. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
5. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
6. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
8. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
9. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
10. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
11. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... NYSE: SNY) today announced that the Companies intend to ... pediatric disease priority review voucher in connection with the ... review voucher entitles the holder to designate a BLA ... review from the filing date instead of the standard ...
(Date:7/30/2014)... 30, 2014  Replikins Ltd. today released new data ... virus. Before the current outbreaks, the mean Ebola Reston ... acids) between 1995 and 2002 was 1.1; the mean ... and sixteen-fold in 2013, thus predicting the current outbreaks ... has been shown to be able to predict outbreaks ...
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... 2012  Foundation for Health Improvement and Technology (FHIT), ... its nonprofit, with the mission to rid the ... through educational programs promoting early detection and aggressive ... research have made it entirely possible to detect ...
... Francisco, CA (March 14, 2012): A highly targeted ... O104 strain was rapidly created using AvidBiotics, antibacterial ... published, draft genomic sequence data as detailed in a ... strategy described offers a rapid-response platform with the potential ...
... of a specialist field to identify subject experts and ... bewildering. New research, published in BioMed Central,s open access ... method of social network analysis, similar to finding friends ... news articles to identify opinion leaders and media experts. ...
Cached Biology Technology:Foundation for Health Improvement and Technology (FHIT) Launched to Beat Cardiovascular Disease 2Targeted antibacterial agent rapidly created in response to serious food safety pathogen 2Targeted antibacterial agent rapidly created in response to serious food safety pathogen 3Social networking shortcut to finding medical experts 2
(Date:7/30/2014)... Press Limited today announced an across-the-board increase in ... The 2013 InCites Journal Citation Reports (Thomson Reuters, ... Biochemical Journal , Essays in Biochemistry , ... Reports all received increases in their Impact ... Society and published by Portland Press Limited. , ...
(Date:7/30/2014)... State University,s College of Engineering recently received a ... the project, "Nanoparticle-directed synthesis of organic nanorods." ... is the creation and utilization of functional materials, ... A major bottleneck in scaling up nanotechnology is ... functional materials into one device. A research team ...
(Date:7/30/2014)... Embryonic stem cells can develop into a multitude of cells ... development into the specific types of mature cells that make ... , One key seems to be long chains of sugars ... Godula,s group at the University of California, San Diego, has ... sugars, but can be more easily manipulated to direct the ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... New South Wales (UNSW) researchers have announced they are developing ... to treat a diverse range of health problems, from inflammation ... is published in the July issue of Nature Biotechnology. ... age-related macular degeneration (AMD) and diabetic retinopathy are likely to ...
... Physicians and surgeons will someday monitor a patient's blood ... thanks to research being conducted by a Cornell University ... new technology is being developed by Edwin Kan, associate ... Transonic Systems of Ithaca. Kan performed much of his ...
... factors that would explain the different life expectancies of ... universal, according to University of Michigan researchers. , "Women ... difference in lifespan has been recognized since at least ... scientist in the U-M School of Public Health and ...
Cached Biology News:'Molecular assassin' targets disease gene 2Researchers to develop ultra-miniature implantable sensors to measure blood flow 2Evolutionary forces explain why women live longer than men 2